FOLH1 and Familial prostate cancer: MLN2704, an immunoconjugate designed to deliver an anti-microtubule agent drug directly to PSMA-expressing cells via the PSMA-targeted monoclonal antibody MLN591, shows cytotoxic anti-prostate cancer activity with mild toxicities, predictable pharmacokinetics, and no measurable immunogenicity [12].